Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fitusiran
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR-439774 (fitusiran) is an investigational, subcutaneously administered small interference RNA therapeutic in development for the prophylactic treatment of people with hemophilia A or B, with or without inhibitors.
Product Name : SAR439774
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Fitusiran
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BIVV001 (efanesoctocog alfa) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels for most of the week, extending bleed protection in a once-weekly dose for people with haemophili...
Product Name : BIVV001
Product Type : Protein
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BIVV001 (efanesoctocog alfa) is a novel and investigational recombinant factor VIII therapy that is designed to extend protection from bleeds with once-weekly prophylactic dosing for people with hemophilia A.
Product Name : BIVV001
Product Type : Protein
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fitusiran
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR-439774 (fitusiran) is an investigational, subcutaneously administered small interference RNA therapeutic in development for the prophylactic treatment of people with hemophilia A or B, with or without inhibitors.
Product Name : SAR439774
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 07, 2022
Lead Product(s) : Fitusiran
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Investigational once-weekly BIVV001 (efanesoctocog alfa) prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection for people with severe hemophilia A.
Product Name : BIVV001
Product Type : Protein
Upfront Cash : Inapplicable
October 07, 2022
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study met the primary endpoint, showing a clinically meaningful prevention of bleeds in people with severe hemophilia A receiving weekly prophylaxis with BIVV001 (efanesoctocog alfa) over a period of 52 weeks.
Product Name : BIVV001
Product Type : Protein
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation for Hemophilia A
Details : BIVV001 (efanesoctocog alfa) is a novel and investigational factor VIII therapy designed to provide normal to near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen.
Product Name : BIVV001
Product Type : Protein
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Givosiran
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from phase 3 studies achieved primary and secondary endpoints for ALN-AT3SC (Fitusiran) prophylaxis demonstrated significant and clinically meaningful improvements in bleed protection across all study populations.
Product Name : ALN-AT3SC
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 14, 2021
Lead Product(s) : Givosiran
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi's Efanesoctocog Alfa Granted FDA Fast Track Designation for treatment of hemophilia A
Details : Efanesoctocog alfa, previously known as BIVV001, is an investigational factor VIII replacement therapy that has the potential to transform therapy and provide high sustained factor activity levels for people with hemophilia A.
Product Name : BIVV001
Product Type : Protein
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Efanesoctocog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avalglucosidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Priority Review for Avalglucosidase Alfa, a Potential New Therapy for Pompe Disease
Details : In patients with late-onset Pompe disease (LOPD), 5.5 years of safety and exploratory efficacy results showed avalglucosidase alfa was well-tolerated and stabilized pulmonary and motor function.
Product Name : Nexviazyme
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : Avalglucosidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable